

- **Name:** Dr Amit Kumar
- **Current Position & Affiliation:** Associate Director, Medical Oncology, Hemato-oncology and BMT, Jay Prabha Medanta Superspeciality Hospital, Patna, India
- **Country:** India

• Educational Background:

INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
PATNA MEDICAL COLLEGE, PATNA, INDIA	MBBS	2000-2005	GENERAL MEDICINE
INSTITUTE OF MEDICAL SCIENCE, BANARAS HINDU UNIVERSITY, VARANASI, INDIA	MD	2010-2013	
ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI, INDIA		2013-2016	
TATA MEMORIAL HOSPITAL, MUMBAI, INDIA	DM DNB	2016-2019 2020	MEDICAL ONCOLOGY MEDICAL ONCOLOGY
MRCP, UK ECMO	MRCP-SCE ECMO	2021 2021	MEDICAL ONCOLOGY

• Professional Experience:

INSTITUTION AND LOCATION	Position	YEAR(s)	Remarks
PATNA MEDICAL COLLEGE AND HOSPITAL, PATNA, INDIA	INTERN	2006-2007	Received “ Honours ” (Highest marks) in ANATOMY and COMMUNITY MEDICINE
ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI, INDIA	JUNIOR RESIDENT	2007	Worked in Department of Orthopaedics for 3 months and Department of Surgery for 3 months along with Renal Transplant Unit
DULHIN BAZAR PRIMARY HEALTH CENTRE, PATNA RURAL, INDIA	MEDICAL OFFICER	2007-2009	Worked in field of primary care, immunisation, trauma and reproductive and child health
PATNA MEDICAL COLLEGE AND HOSPITAL, PATNA, INDIA	JUNIOR RESIDENT	2009-2010	Pursued Diploma in Child Health
INSTITUTE OF MEDICAL SCIENCE, BANARAS HINDU UNIVERSITY, VARANASI, INDIA	JUNIOR RESIDENT	2010-2013	Pursued MD General Medicine. Received Gold Medal for best resident
ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS), NEW DELHI, INDIA	SENIOR RESIDENT	2013-2016	Residency in Medical Oncology and Haematopoietic stem cell transplant
TATA MEMORIAL HOSPITAL, MUMBAI, INDIA	SENIOR RESIDENT	2016-2019	Completed Super-specialisation in Medical Oncology.. Presented poster at ESMO ASIA ,Singapore and at IOSICON, Mumbai.
TATA MEMORIAL HOSPITAL, MUMBAI, INDIA	SPECIALIST REGISTRAR	2019-2020	Involved in patient care, education and research in medical oncology, hemato-oncology and bone marrow transplant.
MAHAVIR CANCER SANSTHAN, PATNA, INDIA	SENIOR CONSULTANT	2020-2021	

JAY PRABHA SUPERSPECIALITY PATNA, INDIA	MEDANTA HOSPITAL,	ASSOCIATE DIRECTOR	2021- till date	
---	----------------------	-----------------------	--------------------	--

• Professional Organizations:

1. American Society of Clinical Oncology (ASCO), Alexandria, VA.
2. European Society of Medical Oncology,
3. Indian Society of Medical and Pediatric Oncology, India
4. Indian Medical Association (IMA), New Delhi, India.

• Main Scientific Publications:

1. **Kumar, A., Kapoor, A., Noronha, V. et al.** Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings. **BJC Rep** 2, 35 (2024). <https://doi.org/10.1038/s44276-024-00055-9>. (+ESMO ASIA 2020 poster)
2. **Kumar A, Kapoor A, Prabhash K et al.** Efficacy and Safety of Low-Dose Nivolumab in Treatment of Advanced Solid Tumors: A Retrospective Audit from Resource-Constrained Settings. **South Asian J Cancer**. 2024 Jul 31;14(1):70-76. <https://doi.org/10.1055/s-0044-1788649>. (+ESMO 2020 poster)
3. **Kumar A, Patil VM, et al.** Long-term outcomes of locally advanced and borderline resectable esthesio neuroblastoma and sinonasal tumor with neuroendocrine differentiation treated with neoadjuvant chemotherapy. **Journal of Clinical Oncology** 2020 38:15_suppl, e18507-e18507 (+ASCO 2020 poster)
4. **Kumar A, Kumar L et al** Acute Kidney Injury in Newly Diagnosed Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy: Experience of a Tertiary Cancer in India. **Annals of Oncology** (2017) 28 (suppl_10): x94-x99. 10.1093/annonc/mdx664. (+ESMO 2017 poster)
5. Kapoor A, Gupta A, **Kumar A** et al. Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study). **JCO Glob Oncol**. 2025;11:e2500032. doi:10.1200/GO-25-00032
6. Ramaswamy A, Srinivas S, Lavingia V, **Kumar A** et al. Consensus Statements for Clinical Practice in Advanced/Metastatic Colorectal Cancers in India Using a Modified Delphi Method. **South Asian J Cancer**. 2025;CC BY-NC-ND 4.0. doi:10.1055/s-0045-1809380.
7. Ramaswamy A, Nayak L, Joshi A, **Kumar A**, Prabhash K. et al COVID-19 in cancer patients on active systemic therapy - Outcomes from LMIC scenario with an emphasis on need for active treatment. **Cancer Med**. 2020 Dec;9(23):8747-8753. doi: 10.1002/cam4.3423. Epub 2020 Oct 31. PMID: 33128509; PMCID: PMC7724305.
8. Patil V, **Kumar A**, Prabhash K et al. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. **Lancet Glob Health**. 2020 Sep;8(9):e1213-e1222. doi: 10.1016/S2214-109X(20)30275-8..
9. Ramaswamy A, Kothari R, **Kumar A** ,et al. Adjuvant chemotherapy in stage II–III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX. **South Asian J Cancer** 2019Jul-Sep;8(3):160.https://dx.doi.org/10.4103%2Fsajc.sajc_176_18. <https://www.ncbi.nlm.nih.gov/pubmed/31489288>
10. Joshi Amit, Patil Vijay Maruti, **Kumar Amit**, Prabhash Kumar (2021) **Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation – a phase 3 study** **ecancer** 15 1318. <https://doi.org/10.3332/ecancer.2021.1318>
11. Bhargava PG, **Kumar A**, Ramaswamy A. Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas-A Relatively Rare Component of Biliary Tract Cancers in India. **South Asian J Cancer**. 2020 Oct;9(4):209-212. doi: 10.1055/s-0041-1726140. Epub 2021 Jun 12. PMID: 34268260; PMCID: PMC8276750.
12. Kapoor A, Noronha V, **Kumar A**, Patil V, et al. Clinical profile, practice pattern, and outcomes with first-line therapy in ALK-positive lung cancer: real-world data from resource-constrained settings. **JTO Clin Res Rep**. 2023;4:100443. <https://doi.org/10.1016/j.jtocrr.2022.100443>